1
|
Slow Off-Rate Modified Aptamer (SOMAmer) Proteomic Analysis of Patient-Derived Malignant Glioma Identifies Distinct Cellular Proteomes. Int J Mol Sci 2021; 22:ijms22179566. [PMID: 34502484 PMCID: PMC8431317 DOI: 10.3390/ijms22179566] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2021] [Revised: 08/30/2021] [Accepted: 08/31/2021] [Indexed: 02/04/2023] Open
Abstract
Malignant gliomas derive from brain glial cells and represent >75% of primary brain tumors. This includes anaplastic astrocytoma (grade III; AS), the most common and fatal glioblastoma multiforme (grade IV; GBM), and oligodendroglioma (ODG). We have generated patient-derived AS, GBM, and ODG cell models to study disease mechanisms and test patient-centered therapeutic strategies. We have used an aptamer-based high-throughput SOMAscan® 1.3K assay to determine the proteomic profiles of 1307 different analytes. SOMAscan® proteomes of AS and GBM self-organized into closely adjacent proteomes which were clearly distinct from ODG proteomes. GBM self-organized into four proteomic clusters of which SOMAscan® cluster 4 proteome predicted a highly inter-connected proteomic network. Several up- and down-regulated proteins relevant to glioma were successfully validated in GBM cell isolates across different SOMAscan® clusters and in corresponding GBM tissues. Slow off-rate modified aptamer proteomics is an attractive analytical tool for rapid proteomic stratification of different malignant gliomas and identified cluster-specific SOMAscan® signatures and functionalities in patient GBM cells.
Collapse
|
2
|
Wallace TC, Bultman S, D'Adamo C, Daniel CR, Debelius J, Ho E, Eliassen H, Lemanne D, Mukherjee P, Seyfried TN, Tian Q, Vahdat LT. Personalized Nutrition in Disrupting Cancer - Proceedings From the 2017 American College of Nutrition Annual Meeting. J Am Coll Nutr 2018; 38:1-14. [PMID: 30511901 DOI: 10.1080/07315724.2018.1500499] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Cancer is a major public health problem and is the second leading cause of death in the United States and worldwide; nearly one in six deaths are attributable to cancer. Approximately 20% of all cancers diagnosed in the United States are attributable to unhealthy diet, excessive alcohol consumption, physical inactivity, and body fatness. Individual cancers are distinct disease states that are multifactorial in their causation, making them exceedingly cumbersome to study from a nutrition standpoint. Genetic influences are a major piece of the puzzle and personalized nutrition is likely to be most effective in disrupting cancer during all stages. Increasing evidence shows that after a cancer diagnosis, continuing standard dietary recommendations may not be appropriate. This is because powerful dietary interventions such as short-term fasting and carbohydrate restriction can disrupt tumor metabolism, synergizing with standard therapies such as radiation and drug therapy to improve efficacy and ultimately, cancer survival. The importance of identifying dietary interventions cannot be overstated, and the American College of Nutrition's commitment to advancing knowledge and research is evidenced by dedication of the 2017 ACN Annual Meeting to "Disrupting Cancer: The Role of Personalized Nutrition" and this resulting proceedings manuscript, which summarizes the meeting's findings.
Collapse
Affiliation(s)
- Taylor C Wallace
- a Department of Nutrition and Food Studies , George Mason University , Fairfax, VA , USA.,b Think Healthy Group, Inc , Washington, DC , USA
| | - Scott Bultman
- c Department of Genetics, University of North Carolina School of Medicine
| | - Chris D'Adamo
- d Departments of Family and Community Medicine and Epidemiology and Public Health , Center for Integrative Medicine, University of Maryland School of Medicine
| | - Carrie R Daniel
- e Department of Epidemiology, Division of Cancer Prevention and Population Sciences , The University of Texas MD Anderson Cancer Center
| | - Justine Debelius
- f Department of Medical Epidemiology and Biostatistics , Karolinska Institute , Stockholm , Sweden
| | - Emily Ho
- g Moore Family Center for Whole Grain Foods, Nutrition and Preventive Health, School of Biological and Population Health Sciences, Linus Pauling Institute, Oregon State University
| | - Heather Eliassen
- h Channing Division of Network Medicine , Brigham and Women's Hospital and Harvard Medical School.,i Harvard T.H. Chan School of Public Health
| | - Dawn Lemanne
- j Department of Medicine , University of Arizona , Tucson.,k National Institute of Integrative Medicine , Melbourne , Australia.,l Oregon Integrative Oncology , Ashland , Oregon
| | | | | | - Qiang Tian
- n Institute for Systems Biology, P4 Medicine Institute
| | | |
Collapse
|
3
|
Kameda-Smith MM, Manoranjan B, Bakhshinyan D, Adile AA, Venugopal C, Singh SK. Brain tumor initiating cells: with great technology will come greater understanding. FUTURE NEUROLOGY 2017. [DOI: 10.2217/fnl-2017-0011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The discovery of the brain tumor initiating cells resulted in a paradigm shift within the cancer research community to consider brain tumors as an outcome of developmental mechanisms gone awry. This review will guide the reader through the technological advances that hold the powerful potential to allow brain cancer researchers to develop an intimate understanding of the dynamic and complex mechanism governing brain tumor behavior.
Collapse
Affiliation(s)
- Michelle M Kameda-Smith
- Stem Cell & Cancer Research Institute (SCC-RI), McMaster University, Michael DeGroote Center for Learning & Discovery, Room 5061, 1200 Main Street West, Hamilton, Ontario, L8S 4K1, Canada
- Division of Neurosurgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada
| | - Branavan Manoranjan
- Stem Cell & Cancer Research Institute (SCC-RI), McMaster University, Michael DeGroote Center for Learning & Discovery, Room 5061, 1200 Main Street West, Hamilton, Ontario, L8S 4K1, Canada
| | - David Bakhshinyan
- Stem Cell & Cancer Research Institute (SCC-RI), McMaster University, Michael DeGroote Center for Learning & Discovery, Room 5061, 1200 Main Street West, Hamilton, Ontario, L8S 4K1, Canada
| | - Ashley A Adile
- Stem Cell & Cancer Research Institute (SCC-RI), McMaster University, Michael DeGroote Center for Learning & Discovery, Room 5061, 1200 Main Street West, Hamilton, Ontario, L8S 4K1, Canada
| | - Chitra Venugopal
- Stem Cell & Cancer Research Institute (SCC-RI), McMaster University, Michael DeGroote Center for Learning & Discovery, Room 5061, 1200 Main Street West, Hamilton, Ontario, L8S 4K1, Canada
| | - Sheila K Singh
- Stem Cell & Cancer Research Institute (SCC-RI), McMaster University, Michael DeGroote Center for Learning & Discovery, Room 5061, 1200 Main Street West, Hamilton, Ontario, L8S 4K1, Canada
- Division of Neurosurgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada
| |
Collapse
|
4
|
"A Future Amalgamation Between the Scientist and the Clinician?". Methods Mol Biol 2017. [PMID: 28523494 DOI: 10.1007/978-1-4939-7051-3_1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register]
Abstract
Personalized medicine is gaining momentum and analytical methods such as MS are ideally situated to provide coherent imaging of human disease. The cancer research field is already starting to benefit from the MS imaging applications; non-cancerous diseases will hopefully enjoy the same success. Often, the way forward is to embrace several techniques, which can complement and verify each other. This approach can be seen as less confrontational as everyone can play a part in the development of a new working practice. Stakeholders, professional bodies, and instrument manufacturers will be open to maximizing the patient benefit; investment is more likely given the past performance and reputation of the collaborative highly skilled team.With this in mind, how close are we to a future amalgamation between the scientist and the clinician? Can we accelerate the integration of innovative bench technologies into the clinical setting and bring state-of-the-art imaging diagnostics to the patient bedside or General Practitioners treatment room?
Collapse
|
5
|
Twiss JL, Fainzilber M. Neuroproteomics: How Many Angels can be Identified in an Extract from the Head of a Pin? Mol Cell Proteomics 2016; 15:341-3. [PMID: 26729708 DOI: 10.1074/mcp.e116.057828] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2016] [Indexed: 11/06/2022] Open
Affiliation(s)
- Jeffery L Twiss
- From the ‡Department of Biological Sciences, University of South Carolina, Columbia, South Carolina 29208;
| | - Mike Fainzilber
- §Department of Biological Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel
| |
Collapse
|